Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin - Tolmar

Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; LA 2575; Leuprogel®; SOT-375; SOU 375

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT USA
  • Developer Tolmar
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Precocious puberty
  • Discontinued Endometriosis

Most Recent Events

  • 05 Sep 2018 Tolmar completes a phase III trial in Precocious puberty (In children) in Canada, Chile, Mexico, Argentina, New Zealand (SC) (NCT02452931)
  • 19 Feb 2018 TOLMAR Australia has been acquired by Mundipharma (China) Pharmaceutical
  • 15 May 2017 Pooled pharmacokinetics data from four pivotal studies in Prostate cancer presented at the 112th Annual American Urological Association Meeting in Boston (AUA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top